Advaxis, Inc. Expands Collaboration With GRU Cancer Center At Georgia Regents University To Conduct Four Cancer Immunotherapy Clinical Trials
Published: Feb 05, 2014
PRINCETON, N.J., Feb. 5, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, announced it has expanded its relationship by entering into a master clinical trial agreement with GRU Cancer Center to conduct four Phase 1/2 clinical trials. The trials will be conducted under the supervision of Dr. Samir Khleif, Director, GRU Cancer Center and former Chief of the Vaccines Section at the National Cancer Institute (NCI).
Help employers find you! Check out all the jobs and post your resume.